Neurobiology and Management of Attention-Deficit/Hyperactivity Disorder and Co-Occurring Major Depressive Disorder: Complications and Strategies

B. Kayongo
{"title":"Neurobiology and Management of Attention-Deficit/Hyperactivity Disorder and Co-Occurring Major Depressive Disorder: Complications and Strategies","authors":"B. Kayongo","doi":"10.36349/EASJPP.2020.V02I06.005","DOIUrl":null,"url":null,"abstract":"Quick Response Code Abstract: Attention-deficit/hyperactivity disorder (ADHD) is a contentious diagnostic issue, which has been increasing in prevalence in recent years, and is often comorbid with major depressive disorder (MDD). The common features of ADHD and MDD are altered activation of brain regions involved in rewarding processing and monoamine signalling. ADHD responds well to a multimodal treatment that consists of pharmacological and psychosocial interventions. Its treatment responsiveness improves mood and well-being. There is persistent debate around the use of catecholaminergic agents such as psychostimulants both in ADHD and in the treatment of depression. This review will focus on the neurobiology of both psychopathologies and how they intertwine, and consider the potential benefits and adverse effects of catecholaminergic agents in the treatment of ADHD and co-occurring MDD.","PeriodicalId":328128,"journal":{"name":"EAS Journal of Pharmacy and Pharmacology","volume":"15 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EAS Journal of Pharmacy and Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36349/EASJPP.2020.V02I06.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Quick Response Code Abstract: Attention-deficit/hyperactivity disorder (ADHD) is a contentious diagnostic issue, which has been increasing in prevalence in recent years, and is often comorbid with major depressive disorder (MDD). The common features of ADHD and MDD are altered activation of brain regions involved in rewarding processing and monoamine signalling. ADHD responds well to a multimodal treatment that consists of pharmacological and psychosocial interventions. Its treatment responsiveness improves mood and well-being. There is persistent debate around the use of catecholaminergic agents such as psychostimulants both in ADHD and in the treatment of depression. This review will focus on the neurobiology of both psychopathologies and how they intertwine, and consider the potential benefits and adverse effects of catecholaminergic agents in the treatment of ADHD and co-occurring MDD.
注意缺陷/多动障碍和共发性抑郁症的神经生物学和管理:并发症和策略
摘要注意缺陷多动障碍(Attention-deficit hyperactivity disorder, ADHD)是一个有争议的诊断问题,近年来发病率不断上升,且常与重度抑郁症(MDD)合并症。ADHD和MDD的共同特征是涉及奖励处理和单胺信号传导的大脑区域的激活改变。ADHD对包括药理学和社会心理干预在内的多模式治疗反应良好。它的治疗反应性改善了情绪和健康。关于儿茶酚胺能药物(如精神兴奋剂)在多动症和抑郁症治疗中的使用一直存在争议。这篇综述将着重于这两种精神病理学的神经生物学及其相互关系,并考虑儿茶酚胺能药物治疗ADHD和合并MDD的潜在益处和不良影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信